Chinese consensus on the use of antiarrhythmic drugs for rhythm control in atrial fibrillation.
10.3760/cma.j.cn112138-20220402-00241
- Author:
Yi Hong SUN
1
;
Nian LIU
2
;
Yu Mei XUE
3
;
Chang Sheng MA
2
;
Shu Lin WU
3
Author Information
1. Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China.
2. Department of Cardiology, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, China.
3. Department of Cardiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Anti-Arrhythmia Agents/therapeutic use*;
Atrial Fibrillation/drug therapy*;
Consensus;
China
- From:
Chinese Journal of Internal Medicine
2023;62(4):343-355
- CountryChina
- Language:Chinese
-
Abstract:
Rhythm control is crucial part of comprehensive management of atrial fibrillation (AF). Rhythm control can reduce the burden of AF effectively, reduce symptoms, and improve the prognosis in early AF. Antiarrhythmic drugs (AADs) are the first-line treatment for rhythm-control strategies. This consensus focuses on the principle of rhythm control in AF, the characteristics of AADs, and the medication recommendations for patients in different populations suffering from AF. Hence, this consensus aims to support clinical decision-making for AF therapy.
